Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Essential1OLE: Change in mADL11 from Baseline, By Study week Weekly change from week 8 in…
Month: August 2023
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –…
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
Acacia Quarterly Sales and Growth Table one • Total revenue for Q2 2023 was $64.6…